GlassScriptPhysician profile
Tulio A Diaz
NPI 1992739270
$5,183.08
in general payments reported to CMS, 2019-2025
25 companies · $58.45 in 2025
The $58.45 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,235 · 2020: $467 · 2021: $332 · 2022: $317 · 2023: $344 · 2024: $429 · 2025: $58.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,348.67 | 2019-2024 | Impella |
| Endologix LLC | $702.64 | 2019-2020 | |
| Boston Scientific Corporation | $529.31 | 2019-2022 | |
| Intact Vascular, INC. | $317.43 | 2019 | |
| Philips North America LLC | $251.50 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $201.60 | 2023-2024 | |
| W. L. Gore & Associates, INC. | $149.51 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.01 | 2019-2025 | Lifevest |
| Cardiovascular Systems INC. | $94.07 | 2019-2020 | |
| Pfizer INC. | $62.06 | 2022-2025 | |
| Heartflow, INC. | $50.25 | 2022 | |
| Novo Nordisk INC | $47.04 | 2022-2023 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $41.49 | 2023 | Camzyos |
| Esperion Therapeutics, INC. | $34.62 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $33.55 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cagent Vascular INC | $31.17 | 2023 | Serrantor |
| Chiesi USA, INC. | $31.05 | 2020 | |
| Amarin Pharma, INC. | $16.41 | 2021 | |
| Angiodynamics, INC. | $15.81 | 2019 | |
| Amgen INC. | $15.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Abbott Laboratories | $13.43 | 2023 | Jeti |
| Sanofi-Aventis U.S. LLC | $13.39 | 2021 | |
| Tactile Systems Technology INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulio Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.